TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC lessened its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 38.2% during the second quarter, Holdings Channel.com reports. The firm owned 323,350 shares of the company’s stock after selling 200,070 shares during the quarter. TransMedics Group makes up 2.0% of Emerald Advisers LLC’s investment portfolio, making the stock its 4th largest position. Emerald Advisers LLC’s holdings in TransMedics Group were worth $48,703,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Los Angeles Capital Management LLC lifted its holdings in shares of TransMedics Group by 20.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 9,307 shares of the company’s stock valued at $1,402,000 after buying an additional 1,551 shares during the period. Wakefield Asset Management LLLP purchased a new position in TransMedics Group in the second quarter worth $1,049,000. Private Advisor Group LLC lifted its holdings in TransMedics Group by 230.6% in the second quarter. Private Advisor Group LLC now owns 10,017 shares of the company’s stock valued at $1,509,000 after acquiring an additional 6,987 shares during the period. Arizona State Retirement System boosted its position in shares of TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after purchasing an additional 186 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of TransMedics Group by 3.9% during the 2nd quarter. Rhumbline Advisers now owns 47,645 shares of the company’s stock worth $7,176,000 after purchasing an additional 1,783 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 2.4 %

Shares of TMDX opened at $139.88 on Friday. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm has a 50 day simple moving average of $154.82 and a 200-day simple moving average of $124.58. The stock has a market cap of $4.67 billion, a price-to-earnings ratio of -411.41 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the business posted ($0.03) earnings per share. TransMedics Group’s revenue was up 117.7% compared to the same quarter last year. Equities analysts forecast that TransMedics Group, Inc. will post 1.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on TMDX. Needham & Company LLC initiated coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective for the company. Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. TD Cowen boosted their price target on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Cantor Fitzgerald began coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Finally, Morgan Stanley boosted their target price on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.44.

Insider Buying and Selling

In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the sale, the director now directly owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,247 shares of company stock worth $9,551,089. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.